Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants

J Child Adolesc Psychopharmacol. 2020 Mar;30(2):81-86. doi: 10.1089/cap.2019.0105. Epub 2019 Oct 17.

Abstract

Objective: To examine medication prescribing patterns for preschool-aged children with diagnoses of attention-deficit/hyperactivity disorder (ADHD) and/or disruptive behavior disorder (DBD). Secondary objectives included determining if prescription patterns varied by gender, insurance type, or comorbid diagnosis of autism spectrum disorder (ASD). Methods: A retrospective, cross-sectional chart review was completed for children ages 2-5 years who were treated at an academic medical center between 2013 and 2016 with a diagnosis of ADHD and/or DBD. Data were analyzed by Fisher's exact and chi-square tests and Cochran-Armitage trend analysis. Results: Of the 966 children who met inclusion criteria, 343 (35.5%) were prescribed ADHD medications. For 2-, 3-, and 4-year olds, the most commonly prescribed medication was an alpha agonist (AA), while for 5-year olds, methylphenidate (MPH) was most commonly prescribed. With advancing age, an increasing number of children were prescribed a stimulant medication and a decreasing number of children were prescribed an AA (p < 0.001). Children were more often prescribed an MPH formulation (48.2%) compared with amphetamine-based stimulants (26.8%). Children without ASD were more likely to be prescribed a stimulant medication (72.1%) when compared with children with ASD (37.0%, p < 0.0001). Children with private insurance were more likely to be prescribed an extended-release stimulant medication when compared with Medicaid patients (34.3% vs. 17.2%, p = 0.004). Conclusion: Both stimulants and nonstimulants are being prescribed regularly in very young children, even before the age of four at an academic medical center. AAs were the most commonly prescribed medication for children 2, 3, and 4 years of age with diagnoses of ADHD, DBD, and ASD. Insurance type, comorbid diagnosis of ASD, and age of child were found to be significantly associated with prescribing a nonpreferred medication.

Keywords: ADHD; pharmacotherapy; preschool.

MeSH terms

  • Adrenergic alpha-Agonists / administration & dosage*
  • Age Factors
  • Amphetamine / administration & dosage
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit and Disruptive Behavior Disorders / drug therapy*
  • Autism Spectrum Disorder / drug therapy
  • Central Nervous System Stimulants / administration & dosage*
  • Child, Preschool
  • Cross-Sectional Studies
  • Female
  • Humans
  • Insurance, Health / statistics & numerical data
  • Male
  • Medicaid / statistics & numerical data
  • Methylphenidate / administration & dosage
  • Practice Patterns, Physicians' / statistics & numerical data
  • Retrospective Studies
  • United States

Substances

  • Adrenergic alpha-Agonists
  • Central Nervous System Stimulants
  • Methylphenidate
  • Amphetamine